Literature DB >> 31551033

T cell-specific STAT3 deficiency abrogates lupus nephritis.

N Yoshida1,2, F He1, V C Kyttaris1,2.   

Abstract

Signal transducer and activator of transcription (STAT) 3 is a regulator of T-cell responses to external stimuli, such as pro-inflammatory cytokines and chemokines. We have previously shown that STAT3 is activated (phosphorylated) at high levels in systemic lupus erythematosus (SLE) T cells and mediates chemokine-induced migration and T:B cell interactions. Stattic, a small molecular STAT3 inhibitor, can partially ameliorate lupus nephritis in mice. To understand the role of STAT3 better in T-cell pathophysiology in lupus nephritis and its potential as a treatment target, we silenced its expression in T cells using a cd4-driven CRE-Flox model. We found that lupus-prone mice that do not express STAT3 in T cells did not develop lymphadenopathy, splenomegaly, or glomerulonephritis. Moreover, the production of anti-dsDNA antibodies was decreased in these mice compared to controls. To dissect the mechanism, we also used a nephrotoxic serum model of nephritis. In this model, T cell-specific silencing of STAT3 resulted in amelioration of nephrotoxic serum-induced kidney damage. Taken together, our results suggest that in mouse models of autoimmune nephritis, T cell-specific silencing of STAT3 can hamper their ability to help B cells to produce autoantibodies and induce cell tissue infiltration. We propose that STAT3 inhibition in T cells represents a novel approach in the treatment of SLE and lupus nephritis in particular.

Entities:  

Keywords:  SLE; STAT3; T cells; murine lupus; nephritis

Mesh:

Substances:

Year:  2019        PMID: 31551033      PMCID: PMC6791775          DOI: 10.1177/0961203319877242

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

2.  STAT3 regulates cytokine-mediated generation of inflammatory helper T cells.

Authors:  Xuexian O Yang; Athanasia D Panopoulos; Roza Nurieva; Seon Hee Chang; Demin Wang; Stephanie S Watowich; Chen Dong
Journal:  J Biol Chem       Date:  2007-02-03       Impact factor: 5.157

3.  IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.

Authors:  Hong Dai; Fan He; George C Tsokos; Vasileios C Kyttaris
Journal:  J Immunol       Date:  2017-06-23       Impact factor: 5.422

4.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

Authors:  K Takeda; B E Clausen; T Kaisho; T Tsujimura; N Terada; I Förster; S Akira
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

5.  Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.

Authors:  Manjula Reddy; Cuc Davis; Jackson Wong; Paul Marsters; Charles Pendley; Uma Prabhakar
Journal:  Cell Immunol       Date:  2007-08-29       Impact factor: 4.868

6.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration.

Authors:  Tatsuhiro Harada; Vasileios Kyttaris; Yansong Li; Yuang-Taung Juang; Ying Wang; George C Tsokos
Journal:  Autoimmunity       Date:  2007-02       Impact factor: 2.815

8.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Daniel J Wallace; Richard A Furie; Yoshiya Tanaka; Kenneth C Kalunian; Marta Mosca; Michelle A Petri; Thomas Dörner; Mario H Cardiel; Ian N Bruce; Elisa Gomez; Tara Carmack; Amy M DeLozier; Jonathan M Janes; Matthew D Linnik; Stephanie de Bono; Maria E Silk; Robert W Hoffman
Journal:  Lancet       Date:  2018-07-21       Impact factor: 79.321

9.  Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif.

Authors:  Julia Lichtnekert; Volker Vielhauer; Daniel Zecher; Onkar P Kulkarni; Sebastian Clauss; Stephan Segerer; Veit Hornung; Tanya N Mayadas; Bruce Beutler; Shizuo Akira; Hans-Joachim Anders
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

10.  Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

Authors:  Ronald F van Vollenhoven; Bevra H Hahn; George C Tsokos; Carrie L Wagner; Peter Lipsky; Zahi Touma; Victoria P Werth; Robert M Gordon; Bei Zhou; Benjamin Hsu; Marc Chevrier; Manon Triebel; Jarrat L Jordan; Shawn Rose
Journal:  Lancet       Date:  2018-09-21       Impact factor: 79.321

View more
  5 in total

1.  Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells.

Authors:  Li-Jun Du; Yu-Xiang Feng; Zhi-Xing He; Lin Huang; Qiao Wang; Cheng-Ping Wen; Yun Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-09-22       Impact factor: 7.169

2.  Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome.

Authors:  Rishi R Goel; Shuichiro Nakabo; Brian L P Dizon; Amanda Urban; Meryl Waldman; Lillian Howard; Dirk Darnell; Munir Buhaya; Carmelo Carmona-Rivera; Sarfaraz Hasni; Mariana J Kaplan; Alexandra F Freeman; Sarthak Gupta
Journal:  J Allergy Clin Immunol       Date:  2020-08-05       Impact factor: 10.793

3.  IL-27 Protects the Brain from Ischemia-Reperfusion Injury via the gp130/STAT3 Signaling Pathway.

Authors:  Chun Luo; Binru Li; Lang Chen; Lili Zhao; Yinghai Wei
Journal:  J Mol Neurosci       Date:  2021-04-13       Impact factor: 3.444

Review 4.  Cutaneous and systemic connections in lupus.

Authors:  Mitra P Maz; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

Review 5.  Targeting Canonical and Non-Canonical STAT Signaling Pathways in Renal Diseases.

Authors:  Lili Gai; Yuting Zhu; Chun Zhang; Xianfang Meng
Journal:  Cells       Date:  2021-06-27       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.